Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRCENASDAQ:LGVNNASDAQ:QTTBNASDAQ:TCDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRCEGrace Therapeutics$2.93-2.3%$2.76$1.75▼$4.97$30.42M0.8941,281 shs90,421 shsLGVNLongeveron$1.15-4.2%$1.39$1.12▼$6.40$17.91M0.221.40 million shs135,401 shsQTTBQ32 Bio$1.53-1.3%$1.74$1.38▼$53.79$18.66M-0.04199,299 shs81,793 shsTCDATricida$0.13$0.09▼$13.85$6.01M0.2217.62 million shs31.13 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRCEGrace Therapeutics-2.33%+1.38%-1.35%+14.45%+292,999,900.00%LGVNLongeveron-4.17%-10.85%-14.81%-35.39%-47.73%QTTBQ32 Bio-1.29%-8.93%-5.56%-26.44%-90.12%TCDATricida0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRCEGrace Therapeutics1.6595 of 5 stars3.50.00.00.00.00.81.3LGVNLongeveron3.1851 of 5 stars3.65.00.00.00.61.71.3QTTBQ32 Bio2.906 of 5 stars3.14.00.00.03.31.70.6TCDATricidaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRCEGrace Therapeutics 3.00Buy$12.00309.56% UpsideLGVNLongeveron 3.25Buy$8.67653.62% UpsideQTTBQ32 Bio 2.25Hold$12.17695.21% UpsideTCDATricida 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TCDA, QTTB, LGVN, and GRCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025GRCEGrace TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRCEGrace TherapeuticsN/AN/AN/AN/A$6.57 per shareN/ALGVNLongeveron$2.39M7.18N/AN/A$1.47 per share0.78QTTBQ32 Bio$1.16M16.09N/AN/A$0.47 per share3.26TCDATricidaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRCEGrace Therapeutics-$12.85M-$1.16N/AN/AN/AN/A-20.10%-17.10%N/ALGVNLongeveron-$15.97M-$6.28N/AN/AN/A-760.72%-85.07%-70.74%8/13/2025 (Estimated)QTTBQ32 Bio-$47.73M-$4.94N/AN/AN/AN/A-447.33%-59.77%8/6/2025 (Estimated)TCDATricida-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/ALatest TCDA, QTTB, LGVN, and GRCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23-$0.21+$0.02$0.01N/AN/A5/8/2025Q1 2025QTTBQ32 Bio-$1.23-$0.90+$0.33-$0.90N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRCEGrace TherapeuticsN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ATCDATricidaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRCEGrace TherapeuticsN/A6.066.06LGVNLongeveronN/A5.615.61QTTBQ32 Bio1.684.714.71TCDATricidaN/A4.874.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRCEGrace Therapeutics6.08%LGVNLongeveron10.01%QTTBQ32 Bio31.32%TCDATricidaN/AInsider OwnershipCompanyInsider OwnershipGRCEGrace Therapeutics13.51%LGVNLongeveron11.20%QTTBQ32 Bio40.00%TCDATricida35.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRCEGrace TherapeuticsN/A10.14 million8.77 millionN/ALGVNLongeveron2014.93 million13.26 millionNot OptionableQTTBQ32 Bio3912.20 million7.32 millionN/ATCDATricida5755.67 million35.85 millionNot OptionableTCDA, QTTB, LGVN, and GRCE HeadlinesRecent News About These CompaniesTricida CEO to Pay $14 Million in Class Suit Over Drug ProgressMarch 4, 2025 | news.bloomberglaw.comPatrick G Enright's Net WorthMay 5, 2024 | benzinga.comSierraConstellation Partners Receives Industry Recognition for Work with TricidaFebruary 6, 2024 | finance.yahoo.comTricida Inc (TCDAQ)January 13, 2024 | es.investing.comEmerging Therapies in the Treatment of Clostridium difficile-Associated DiseaseMay 30, 2023 | medscape.comVaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo FinanceApril 18, 2023 | news.google.comMetabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital JournalApril 17, 2023 | news.google.comReal-time PCR as a Diagnostic Tool for Bacterial DiseasesApril 12, 2023 | medscape.comChronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital JournalApril 10, 2023 | news.google.comChronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital JournalApril 6, 2023 | news.google.comTricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360March 24, 2023 | news.google.comAlicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo FinanceMarch 14, 2023 | news.google.comAlicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo FinanceMarch 14, 2023 | news.google.comTricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360March 6, 2023 | news.google.comTroubled Adamis To Merge With Private DMK, Focus On ... - ScripMarch 1, 2023 | news.google.comRelease Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360February 27, 2023 | news.google.comRenibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360February 21, 2023 | news.google.comSTONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.comFebruary 18, 2023 | news.google.comTop 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.comFebruary 18, 2023 | news.google.comTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo FinanceFebruary 14, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCDA, QTTB, LGVN, and GRCE Company DescriptionsGrace Therapeutics NASDAQ:GRCE$2.93 -0.07 (-2.33%) As of 06/23/2025 04:00 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Longeveron NASDAQ:LGVN$1.15 -0.05 (-4.17%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.17 +0.02 (+2.09%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Q32 Bio NASDAQ:QTTB$1.53 -0.02 (-1.29%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.56 +0.03 (+1.96%) As of 05:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Tricida NASDAQ:TCDATricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
